Insight Molecular Diagnostics (IMDX) Operating Expenses (2015 - 2026)

Insight Molecular Diagnostics has reported Operating Expenses for 12 years, with the latest figure at $4.4 million in Q1 2026.

• Quarterly Operating Expenses fell 45.49% year-over-year to $4.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $49.7 million (down 17.91% YoY) and the FY2025 annual result came in at $53.4 million, down 13.53% from the prior year.
• Operating Expenses retreated to $4.4 million in Q1 2026 per IMDX's latest filing, from $23.9 million in the prior quarter.
• Over five years, Operating Expenses peaked at $34.2 million in Q4 2024 and troughed at -$5.8 million in Q1 2023.
• A 5-year average of $9.6 million and a median of $8.6 million in 2023 frame the typical range for Operating Expenses.
• The widest YoY moves for Operating Expenses: up 416.96% in 2023, down 278.92% in 2023.
• Over 5 years, Operating Expenses stood at $11.6 million in 2022, then jumped by 38.22% to $16.1 million in 2023, then surged by 113.06% to $34.2 million in 2024, then plunged by 30.07% to $23.9 million in 2025, then tumbled by 81.5% to $4.4 million in 2026.
• According to Business Quant data, Operating Expenses over the past three periods registered $4.4 million, $23.9 million, and $11.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.